N/A
N=90
Overall Performance of a 1-day Silicone Hydrogel Lens When Habitual Soft Lens Wearers Are Refit
Myopia
Bottom Line
View on ClinicalTrials.gov: NCT02588573 ↗Enrolled (actual)
90
Serious AEs
0.0%
Results posted
Feb 2019
Primary outcome: Primary: Comfort — 83; 77; 83; 83 units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- etafilcon A (control) (Device); somofilcon A (test) (Device)
- Age
- Pediatric, Adult, Older Adult · 17+ yrs
- Sex
- All
- Sponsor
- CooperVision, Inc.
- Primary completion
- Mar 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Comfort |
83; 77; 83; 83 | — |
| PRIMARY Comfort Preference |
7; 3; 13; 2; 14; 10 | — |
| PRIMARY Bulbar Hyperemia |
1.3; 1.3; 1.2; 1.2; 1.3; 1.3 | — |
| PRIMARY Limbal Hyperemia |
1.2; 1.2; 1.0; 1.0; 1.2; 1.3 | — |
| PRIMARY Conjunctival Staining |
1.0; 1.1; 1.1; 1.4; 0.4; 1.1 | — |
| PRIMARY Visual Acuity |
-0.05; -0.05; -0.07; -0.06; -0.06; -0.06 | — |
Summary
The objective of the study is to compare the overall subjective comfort profile over 8 hours of lens wear in two groups of habitual soft contact lens wearers (daily disposable hydrogel lenses and frequent replacement lenses) when refitted in to somofilcon A lenses.
Eligibility Criteria
Inclusion Criteria
- A person is eligible for inclusion in the study if he/she:
- Is at least 17 years of age and has full legal capacity to volunteer;
- Has read and signed an information consent letter;
- Is willing and able to follow instructions and maintain the appointment schedule;
- Is correctable to a visual acuity of 20/40 or better (in each eye) with their habitual correction or the assigned study lenses;
- Habitually wears either etafilcon A lens or any frequent replacement contact lenses (as defined in 4.1.1);
- Habitually wear contact lenses with a power between -1.00 and -6.00D (Diopters) (inclusive) in both eyes;
- Demonstrates an acceptable fit with the study lenses;
- Is usually able to wear contact lenses for at least 8 hours per day.
Exclusion Criteria
- A person will be excluded from the study if he/she:
- Is participating in any concurrent clinical or research study;
- Has any known active* ocular disease and/or infection;
- Has a systemic condition that in the opinion of the investigator may affect a study outcome variable;
- Is using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable;
- Has known sensitivity to the diagnostic substances (pharmaceuticals), such as fluorescein dye, or products to be used in the study;
- Is aphakic;
- Has undergone refractive error surgery.
- Has participated in the previous somfofilcon A study (ORE# 20893)
- For the purposes of this study, active ocular disease is defined as infection or inflammation which requires therapeutic treatment. Mild (i.e. not considered clinically relevant) lid abnormalities (blepharitis, meibomian gland dysfunction, papillae), corneal and conjunctival staining and dry eye are not considered active ocular disease. Neovascularization and corneal scars are the result of previous hypoxia, infection or inflammation and are therefore not active.
Data sourced from ClinicalTrials.gov (NCT02588573). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.